Microdosing Under Scrutiny: New Trial Results Challenge Psychedelic Therapy’s Promise
Table of Contents
A recent clinical trial has ignited debate within the burgeoning field of microdosing, raising questions about the validity of reported benefits and the complexities of placebo effects in psychedelic research. The study,conducted by MindBio,has drawn criticism from veteran researcher Jim Fadiman,who pioneered much of the early work on microdosing protocols.
Jim Fadiman, a pioneering researcher whose work laid the groundwork for modern microdosing protocols, has publicly rejected MindBio’s latest findings. His primary concern centers on the trial’s design, which utilized a double-dummy placebo – meaning both the treatment and placebo groups received an active substance, in this case, caffeine. Fadiman argues that the observed improvements in patients may be attributable to the psychoactive properties of caffeine itself, rather than a true placebo response or the effects of LSD.
“Double-dummy is a remarkably apt term,” Fadiman, 86, stated.”What I know is that if you take enough caffeine, you will not be depressed!”
Conflicting Results: Phase 2A vs.Phase 2B Trials
Fadiman points to MindBio’s earlier, Phase 2A study, published in the journal Neuropharmacology, as evidence supporting the potential of microdosing with LSD. This initial trial, an open label study were patients were aware they were receiving LSD, reported a significant 59.5 percent decrease in MADRS (montgomery-Åsberg Depression Rating Scale) scores, with positive effects lasting up to six months. Participants also experienced improvements in stress, rumination, anxiety, and overall quality of life.
“Their prior study did wonderfully with LSD,” Fadiman said. “I have collected literally hundreds of real world reports over the years that validate those findings.”
However, the more recent Phase 2B trial, designed with a higher level of scientific rigor – a triple-blind, double-dummy, active placebo controlled trial – yielded markedly different results.
MindBio Defends Rigorous methodology
According to a company representative, MindBio acknowledges the discrepancy between the Phase 2A and Phase 2B results but maintains the integrity of its research. “We are bewildered at the significant difference between the open label Phase 2A trial results and the Phase 2B trial results,” the representative stated. “but that is the nature of good science-a properly controlled trial will get a proper result. Our Phase 2B trial was of the highest standard, a triple-blind, double-dummy, active placebo controlled trial. I haven’t seen another psychedelic trial that has gone to these lengths to control and blind a trial.”
the Power of Belief: A Personal Account
Despite the scientific debate, the appeal of microdosing persists among some individuals. Ayelet Waldman, author of A Really Good Day, a memoir detailing her self-experimentation with microdosing to treat a mood disorder, expressed a pragmatic perspective. Waldman, also known for her “Mommy-Track Mysteries” series, acknowledged the possibility of a strong placebo effect in her own experience, but ultimately concluded that the subjective improvement in her well-being was paramount.
“In my book I took very seriously the possibility that what I was experiencing was the mother of all placebo effects,” waldman told WIRED. “I wrote about this a number of times in various chapters and decided in the end it didn’t matter. What mattered was that I felt better.”
The ongoing discussion highlights the challenges of studying psychedelic substances and the complex interplay between physiological effects, psychological expectations, and the power of belief. As research continues, a nuanced understanding of these factors will be crucial to unlocking the true potential – and limitations – of microdosing as a therapeutic intervention.
